Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
cyclin-dependent kinase inhibitor |
| gptkbp:approvalYear |
2021
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
L01EF04
|
| gptkbp:brand |
gptkb:Cosela
|
| gptkbp:CASNumber |
1374743-00-6
|
| gptkbp:developedBy |
gptkb:G1_Therapeutics
|
| gptkbp:hasMolecularFormula |
C24H30N8O2
|
| https://www.w3.org/2000/01/rdf-schema#label |
trilaciclib
|
| gptkbp:indication |
Small Cell Lung Cancer
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
CDK4/6 inhibition
|
| gptkbp:pregnancyCategory |
Not recommended
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL3544943
71288861 |
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
gptkb:pneumonia
fatigue headache sepsis hypokalemia hypophosphatemia hypocalcemia |
| gptkbp:UNII |
6QX8J8QK5D
|
| gptkbp:usedFor |
chemotherapy-induced myelosuppression
|
| gptkbp:bfsParent |
gptkb:G1_Therapeutics
|
| gptkbp:bfsLayer |
7
|